Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data

• DOI: 10.1016/j.biopha.2022.112744
• Publication Date: 2022-02-28T20:15:14Z
• Authors: Yoshito Zamami; Takahiro Niimura; Takehiro Kawashiri; Mitsuhiro Goda; Yutaro Naito; Keijo Fukushima; Soichiro Ushio; Fuka Aizawa; Hirofumi Hamano; Naoto Okada; Kenta Yagi; Koji Miyata; Kenshi Takechi; Masayuki Chuma; Toshihiro Koyama; Daisuke Kobayashi; Takao Shimazoe; Hiromichi Fujino; Yuki Izawa-Ishizawa; Keisuke Ishizawa
• Keywords: Dyslipidemia; Medical record

Drug repositioning is a cost-effective method to identify novel disease indications for approved drugs; it requires shorter developmental period than conventional drug discovery methods. We aimed prophylactic drugs oxaliplatin-induced peripheral neuropathy by using data from large-scale medical information and life science databases.Herein, we analyzed the reported between 2007 2017 retrieved FDA's database of spontaneous adverse event reports (FAERS) LINCS provided National Institute Health. The efficacy candidates obtained analysis was examined rat model neuropathy. Additionally, compared incidence in patients who received oxaliplatin at Tokushima University Hospital, Japan. effects statins on animal were six-week-old male Sprague-Dawley rats seven or eight-week-old BALB/C mice. Retrospective chart review included clinical Hospital April 2009 March 2018.Simvastatin, indicated dyslipidemia, significantly reduced severity hyperalgesia. In nerve tissue rats, mRNA expression Gstm1 increased with statin administration. A retrospective revealed that decreased use.Thus, basic databases enables new high probability success.